NEMO HEALTHCARE BV

Their core work

Nemo Healthcare develops non-invasive monitoring technology for unborn babies and pregnant women, focusing on making fetal monitoring safer and more accurate. Based in Veldhoven — the heart of the Netherlands' high-tech ecosystem — the company progressed from feasibility validation to full commercial development of its fetal monitoring solution through the EU SME Instrument. More recently, they contribute their monitoring expertise to an ambitious consortium developing a complete perinatal life support system, including artificial placenta technology for extremely premature infants.

What they specialise in

How they've shifted over time

Nemo Healthcare began with a tightly focused mission: developing and validating their core fetal monitoring device, progressing from SME Instrument Phase 1 (feasibility, 2015) to Phase 2 (full development, 2016-2018). By 2019, they expanded into a broader perinatal life support context through the PLS consortium, contributing their monitoring expertise to a multidisciplinary effort involving artificial placenta, liquid ventilation, and simulation tools. This trajectory shows a company maturing from a single-product startup into a contributor within the wider neonatal intensive care technology landscape.

Moving from standalone fetal monitoring toward integration into comprehensive life support platforms for extremely premature infants — positioning them at the intersection of monitoring hardware and advanced neonatal care.

How they like to work

Nemo Healthcare primarily leads its own projects — two of three H2020 grants were coordinated by them, both focused on their core product. Their participation in the PLS consortium as a partner (not coordinator) shows willingness to contribute specialist expertise within larger teams. With only 4 unique partners across 3 countries, their network is small and focused, typical of a technology SME that collaborates selectively rather than broadly.

A compact network of 4 partners across 3 countries, reflecting selective collaboration. Their partnerships appear driven by the PLS consortium, suggesting connections within the European neonatal medicine and biomedical engineering research community.

What sets them apart

Nemo Healthcare occupies a rare niche: a dedicated SME focused entirely on making fetal monitoring non-invasive and clinically reliable. Their successful progression through both phases of the EU SME Instrument demonstrates validated technology and commercial potential. Located in the Brainport Eindhoven region — Europe's densest concentration of high-tech companies — they have natural access to precision engineering, sensor technology, and medtech talent.

Highlights from their portfolio

• FETAL MONITORING
  Completed the full SME Instrument journey (Phase 1 + Phase 2) with EUR 4.1M total funding — a strong validation signal for their fetal monitoring technology.
• PLS
  Ambitious FET project on artificial placenta and perinatal life support, placing Nemo's monitoring tech within a transformative neonatal care platform running through 2024.